Review
Published on 13 Dec 2024
Single chain fragment variable, a new theranostic approach for cardiovascular diseases
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1443290
- 246 views
Type at least 3 characters
2,784 articles
Articles
Editorial
Published on 12 Dec 2024
Editorial: Single-domain antibodies—biology, engineering and emerging applications, volume II
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1537054
- 284 views
Original Research
Accepted on 11 Dec 2024
A gram-positive enhancer matrix particles vaccine displaying swine influenza virus haemagglutinin protects mice against lethal H1N1 viral challenge
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1432989
- 134 views
Review
Accepted on 11 Dec 2024
DNA Vaccines as Promising Immuno-Therapeutics against Cancer: A New Insight
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1498431
Original Research
Published on 11 Dec 2024
Phage-resistance alters Lipid A reactogenicity: a new strategy for LPS-based conjugate vaccines against Salmonella Rissen
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1450600
- 268 views
Original Research
Published on 11 Dec 2024
Next-generation adjuvant systems containing furfurman drives potent adaptive immunity and host defense as a foot-and-mouth disease vaccine adjuvant
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1491043
- 267 views
Original Research
Accepted on 10 Dec 2024
A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1492464
Original Research
Accepted on 10 Dec 2024
GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1506632
- 112 views
Original Research
Published on 10 Dec 2024
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1496169
- 320 views
Original Research
Accepted on 09 Dec 2024
S6P Mutation in Delta and Omicron Variant Spike Protein Significantly Enhances the Efficacy of mRNA COVID-19 Vaccines
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1495561
- 167 views
Original Research
Accepted on 06 Dec 2024
Comparison of immune responses to SARS-CoV-2 spike after Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1476294
Brief Research Report
Accepted on 06 Dec 2024
Assessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1500622
Review
Accepted on 06 Dec 2024
Development of Nucleic Acid-Based Vaccines Against Dengue and Other Mosquito-Borne Flaviviruses: The Past, Present, and Future
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1475886
Original Research
Published on 05 Dec 2024
Developing a universal multi-epitope protein vaccine candidate for enhanced borna virus pandemic preparedness
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1427677
- 298 views
Original Research
Accepted on 04 Dec 2024
Designing and development of a multi-epitope vaccine against human rhinovirus C utilizing immunoinformatics approach
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1364129
- 169 views
Original Research
Published on 04 Dec 2024
Developing a digital phenotype to subdivide adult immunosuppressed COVID-19 outcomes within the English Primary Care Sentinel Network
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2024.1491565
- 395 views